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Chemotherapy and radiation therapy (RT) are standard therapeutic modalities for patients
with cancers, and could induce various tumor cell deathmodalities, releasing tumor-derived
antigens as well as danger signals that could either be captured for triggering anti-tumor
immune response. Historic studies examining tissue and cellular responses to RT have
predominantly focused on damage caused to proliferating malignant cells leading to their
death. However, there is increasing evidence that RT also leads to signiﬁcant alterations in
the tumor microenvironment, particularly with respect to effects on immune cells and inﬁl-
trating tumors.This review will focus on immunologic consequences of RT and discuss the
therapeutic reprogramming of immune responses in tumors and how it regulates efﬁcacy
and durability to RT.
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INTRODUCTION
The immune system maintains a complex regulatory bal-
ance, maintaining immunological composure despite powerful
immunological stimuli. There can be intense immune activity
at mucosal surfaces and relative inactivity in closely neighboring
sites. Multiple inﬂammatory mechanisms control the location of
immune responsiveness and serve to direct therapeutic responses
to the site of immunological insult. The host remains in a state
of controlled immune activity, regulating the initiation and ter-
mination of immune responses to prevent widespread pathology
is exploited by tumors to overcome the immunogenicity caused
by their antigenicity and aggressive growth. Despite the pres-
ence of immune suppression, even multiply treated patients with
signiﬁcant tumor burden are capable of generating de novo tumor-
speciﬁc immune responses (Laheru et al., 2008). Over the course
of radiation therapy (RT), patients have been shown to develop
tumor antigen-speciﬁc immune responses thatwere not detectable
before treatment demonstrating that immune suppression in
cancer patients and any immune suppression caused by RT is
relative rather than absolute (Nesslinger et al., 2007).
Ionizing radiation is a powerful cytotoxic force that can be
manipulated to speciﬁcally kill cancer cells at target sites. In addi-
tion to thedirect effect of radiation, focal radiation canhavedistant
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CTL, cytotoxic lymphocytes; DAMP, damage-associated molecular patterns; DCs,
dendritic cells; Flt3-L, Fms-like tyrosine kinase receptor 3 ligand; GM-CSF, gran-
ulocyte monocyte-colony stimulating factor; HMGB1, high-mobility group box 1
protein; HSP, heat shock proteins; ICAM, intracellular adhesion molecule; IFN-γ,
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quadratic; LysoPC, lysophosphatidylcholine; MDSCs, myeloid-derived suppressor
cells; MHC, major histocompatibility complex; NF, nuclear factor; NK, natural
killer; OS, overall survival; PSA, prostate serum antigen; RT, radiation therapy;
SABR, stereotactic ablative radiotherapy; SBRT, stereotactic body radiation therapy;
TBI, total-body irradiation; TLR, Toll-like receptor; TNF, tumor necrosis factor;
Tregs, T regulatory cells.
bystander effects that inﬂuence tumor growth outside of the irra-
diated region (Ohba et al., 1998). The abscopal bystander effect
would be an important phenomenon, whether it is intended to
target pre-existing distant metastases or to residual disease that
was not removed by the primary therapy. RT is not always used
alone and clinical translation of radiation therapies that incorpo-
rate immunotherapymust take into account their interaction with
surgery or the multitude of chemotherapies. Both chemotherapy
and RT impact growing cancers through their ability to induce
cell death by disrupting various parameters of cell biology neces-
sary for survival (Haynes et al., 2008; Tesniere et al., 2008; Zitvogel
et al., 2008). Leukocytes detect cell death through immune-based
receptors formolecules released by dying cells (often termed“dan-
ger signals”), such as Toll-like receptor 4 (TLR4) and its ligands
including thehigh-mobility groupbox1protein (HMGB1;Apetoh
et al., 2007).
Effective anti-tumor therapy should induce sufﬁcient tumor
cell death in order to release tumor-associated antigens (TAAs) as
well as danger signals attracting professional antigen-presenting
cells (APCs) phagocytes to uptake and present tumor antigen for
speciﬁc adaptive immunity. Proper cell death modality should be
triggered in both tumor cells, tumor stem cell, and stromal cells.
RT clearly inﬂuences multiple immune-based programs in tissues,
some of which lead to durable tumor regression, whereas oth-
ers propel tumor development. It seems reasonable to conclude
that identifying pathways mediating activation of myeloid-based
protumor immunity induced by RT, will encourage development
of novel therapeutics that suppress those activities to effectively
bolster RT responses. Moreover, blockade of these protumor
immune-based pathways may also present the opportunity to
combine RT with anti-tumor immune-therapeutics to yield effec-
tive and durable suppression of tumors, resulting in improved
outcomes for patients with cancer. In the palliative setting, for
patients who have rituximab and chemotherapy-resistant disease
www.frontiersin.org December 2012 | Volume 2 | Article 191 | 1
“fonc-02-00191” — 2012/12/13 — 20:13 — page 2 — #2
Kaur and Asea Radiation-induced immune responses
and bulky tumors, low-dose RT (LDRT; <1.0 Gy) is an active
and non-toxic treatment modality that might alleviate symptoms
for long periods. Conventional RT remains potentially toxic, par-
ticularly for patients whose disease is located in certain sites. As
with LDRT, rituximab induces apoptosis which is suspected to
contribute to the induction of a speciﬁc anti-lymphoma immune
response in mice (Franki et al., 2008).
IMMUNOGENICITY OF CHEMOTHERAPY AND
RADIOTHERAPY
Cancer research has primarily focused on the role of activating
and/or inactivating mutations in genes regulating aspects of cell
proliferation or cell death. Solid tumors contain neoplastic and
non-neoplastic stromal cells embedded in a dynamic extracellular
matrix (ECM)microenvironment. Cellular components of tumor
stroma include hematogenous and lymphatic vascular cells, inﬁl-
trating and resident leukocytes, various populations of ﬁbroblasts
and mesenchymal support cells unique to each tissue microenvi-
ronment. Increased presence of extra follicular B cells, T regulatory
cells (Tregs) and high ratios of CD4/CD8 and Th1/Th2 T lympho-
cytes in primary tumors or in draining lymph nodes correlates
with tumor grade, stage, and overall survival (OS; Bates et al.,
2006). Inﬁltration of macrophages into the tumor microenvi-
ronment particularly when CD8+ cytotoxic lymphocytes (CTL)
are also present correlates with increased OS (Kawai et al., 2008).
Macrophages exposed to Th1 cytokines including interferon-
gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and gran-
ulocyte monocyte-colony stimulating factor (GM-CSF) exhibit
enhanced cytotoxic activity, production of pro-inﬂammatory
cytokines, and antigen presentation (Figure 1; Mantovani et al.,
2007). On the other hand, macrophages exposed to Th2 cytokines
such as interleukin-4 (IL-4) and IL-13, immune complexes or
immunosuppressive cytokines instead block CTL activity and pro-
mote angiogenesis and tissue remodeling (Figure 1; Ruffell et al.,
2010). The immunological clinical success story in metastatic
melanoma is high-dose IL-2, which causes durable regression of
signiﬁcant disease in a subpopulation of patients (Rosenberg et al.,
1998). Phase I trials with chemotherapy-induced lymphodeple-
tion and adoptive transfer have been performed with impressive
results, showing a 50% response rate in patients with stage IV can-
cer (Dudley et al., 2005). Preclinical data suggested an enhanced
beneﬁt associated with lymphoablative doses of radiation requir-
ing hematopoietic stem cell rescue and these data have been
conﬁrmed in clinical studies where the addition of myeloablative
radiation with hematopoietic stem cell rescue increased response
rates to 72% (Muranski et al., 2006).
Radiation can replicate the effect of vaccination by providing an
alternatemeans to present tumor antigens, it is important to exam-
ine why vaccination and RT synergize. Chakraborty et al. (2004)
demonstrated that RT inﬂuenced the tumor site to render cancer
cells more susceptible to T cell-mediated cytotoxicity, potentially
through upregulation of a range of adhesion molecules (Garnett
et al., 2004). Radiation has been shown to increase the expression
of major histocompatibility complex (MHC) class I, and accentu-
ating this effect via gene therapy increases the therapeutic margin
of radiation. While radiation may have a direct effect on MHC
expression, tumor antigen-speciﬁc cells elicited by radiation can
upregulate IFN-γ in the tumor, and responsiveness to IFN-γ has
been shown to be required for radiation-induced MHC upreg-
ulation. Combination of radiation-induced local inﬂammation
and tumor-speciﬁc effector T cells can together alter the tumor
vasculature, providing an additional mechanism of tumor con-
trol (Ganss et al., 2002). In prostate cancer patients, Gulley et al.
(2005) demonstrated that vaccination with an immunogenic virus
combination expressing the prostate serumantigen (PSA), in com-
bination with radiation and IL-2, resulted in prostate-speciﬁc
immune responses. Direct injection of dendritic cells (DCs) into
tumors undergoing radiation has been shown to increase tumor-
speciﬁc T cell priming and extend survival in murine models
(Teitz-Tennenbaum et al., 2008). CD8 T cell responses play an
important role in the therapeutic outcome of RT in immune-
competent animal models suggesting that therapies targeting T
cells have the potential to enhance this component of therapy in
patients (Lee et al., 2009). Chemotherapy and RT are commonly
believed to kill cancer cells by apoptosis, which is generally con-
sidered as non-immunogenic. Irradiated tumor cells (cell lines
or autologous dissociated tumor pieces) engineered to secrete
GM-CSF are able to mobilize DCs, plasma cells, invariant nat-
ural killer (NK) T cells, and tumor-reactive CD4+ and CD8+
T cells, both in mice and in metastatic cancer patients (Hodi
and Dranoff, 2006). Many chemotherapeutic agents used to treat
malignant diseases damage lymphocytes and consequently sup-
press cell-mediated immunity. New cancer treatment agents such
as tyrosine kinase inhibitors, thalidomide and its derivatives, pro-
teasome inhibitors, and IFNs have been found to have diverse
immunomodulatory activities blocking immune surveillance of
the malignancy and permitting disease recurrence, or, favorably,
by reprogramming immunity to increase autologous anti-tumor
effects.
Traditional fractionated radiation is locally immunosuppres-
sive, dampening local immune responses as they develop due in
part to the fact that lymphocytes are sensitive to radiation doses
and are cleared rapidly from the radiation ﬁeld (Rosen et al., 1999).
Fractionation makes it possible to achieve a therapeutic dose of
radiation to cancer cells while relatively sparing normal tissues
from late toxicities. For example, in standard fractionation for
breast cancer, the radiation dose may be given in 1.8 Gy doses
daily for 6–7 weeks. A single radiation dose of 1.8 Gy will result
in minimal toxicity to normal tissues in the region of the tumor,
with one of the notable exceptions being lymphocytes. Treatment
plans go to signiﬁcant lengths to minimize dose to radiosensi-
tive populations outside of the tumor. Tumor antigen-speciﬁc
T cells can be isolated from many tumors, ampliﬁed in vitro
and restored to full cytolytic function and tumor-draining lymph
nodes are a rich source of tumor antigen-speciﬁc T cells (Robbins
et al., 1996). Therefore, continued tumor radiation for 7 weeks
would severely diminish tumor antigen-speciﬁc T cell populations
through constant site-speciﬁc cytotoxicity. T lymphocytes are
exquisitely sensitive to ionizing radiation with their high turnover
and radiation sensitivity, are effectively ablated by relatively low
radiation doses in an effective immunosuppressive therapy. Deple-
tion of Tregs can remove this suppressive mechanism and restore
anti-tumor immunity (Onizuka et al., 1999). Any T cells intro-
duced into a T cell-deﬁcient environment ﬁnd themselves replete
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FIGURE 1 | Schematic representation of working hypothesis for
RT-induced anti-tumor immune regulation. (1) Within the primary tumor
microenvironment (blue area) untreated tumors express few exposed
tumor-associated antigens (TAAs). (2) Exposure to RT induces the (3) dying
tumors to express signiﬁcantly moreTAAs on their surface and to release
DAMPS, (4) which are both taken up by professional APCs resulting in their
activation. Activation of APC is greatly enhanced (+) by the presence of
Th1-type cytokines and signiﬁcantly suppressed (−) by the presence of
Th2-type cytokine. (5) Activated APCs migrate to draining lymph nodes (DLN;
gray area). (6)Within the DLN, T cell exposure to APC is achieved by direct
contact with activated APCs. (7) ActivatedT cells increase in size and
granularity. (8) The activatedT cells migrate from the DLN as tumor-speciﬁc T
cells (CD8+ CTL) into the tumor microenvironment. (9)Within the tumor
microenvironment CD8+ CTL perform tumor-speciﬁc killing.
in both stimuli, resulting in homeostatic proliferative expansion
to steady-state levels. In the process, T cells take on an acti-
vated phenotype, and have increased cytolytic activity to self
and thus tumor antigens (Gattinoni et al., 2005). It was shown
that in some mouse tumor models complete tumor regression
was achieved following total-body irradiation (TBI). Gattinoni
et al. (2005) likewise were able to show a signiﬁcant increase
in anti-tumor immunity associated with radiation-induced lym-
phodepletion and importantly, that radiation-induced lymphode-
pletion had a greater therapeutic beneﬁt than was observed in a
genetically deﬁcient Rag1-lymphodepletionmodel. Immunostim-
ulatory cytokines including IL-2, IL-12, andTNF-αhave been used
in combination with RT to stimulate anti-tumor T cell responses.
Addition of these pro-inﬂammatory cytokines enhances RT efﬁ-
cacy by bolstering CTL cell responses (Figure 1). Interestingly,
IL-3, a cytokine that activates monocytes and mast cells, delays
tumor growth in response to RT (Oh et al., 2004). Intratumoral
injection of CpG oligodeoxynucleotides that activate TLR9 on
macrophages andDCs resulted in increased RT response and resis-
tance to a second challenge with the same tumor, thus indicating
development of a durable immune response. Antigen presentation
on the surface of DCs to T cells requires both MHC and costim-
ulatory molecules, B7 molecules and OX40. Inhibition of tumor
growth and enhanced OS was also observed in a murine sarcoma
model when RT was given in combination with an agonistic anti-
body for OX40, a costimulatory molecule found on activated T
cells that stimulates T cell proliferation and differentiation. Inhi-
bition of CTLA-4 co-stimulation also enhanced effectiveness of
RT in 4T1 murine mammary carcinomas carcinoma resulting in
diminished metastasis and increased survival, however, RT dose
and timing were critical with regards to anti-CTLA-4 therapy
(Dewan et al., 2009).
Cytokines are peptide-type regulatory proteins, such as the ILs
and lymphokines, released by immune cells leading to generation
of an immune response. Some cytokines act to inhibit immune
responses, e.g., IL-10 and TGF-β, or instead stimulate immune
responses, e.g., TNF-α or IL-1 (Germano et al., 2008). TNF-α
mRNA and protein levels were increased in human sarcoma cells
following RT, an effect that sensitized tumor cells to radiation-
induced cell death. Macrophage-derived IL-1α and IL-1β have
also been found increased in response to RT in vivo following sub-
lethal TBI, as also have IL-6 and TGF-β. Consequences resulting
from the release of these cytokines are recruitment and activation
of leukocytes from peripheral blood and extravasation into tissue
(tumor) parenchyma. Cell adhesion molecules such as ICAM-
1, E-selectin and vascular cell adhesion molecule 1 (VCAM-1)
are upregulated on endothelial cells during inﬂammation and
are critical for leukocyte trafﬁcking across endothelial barriers.
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Vascular endothelial cells within tumor vessels respond to RT
by upregulation of ICAM-1 and E-selectin and thereby facilitate
leukocyte arrest and adhesion prior to transmigration. Blockade of
CD11b, the ligand for ICAM-1, in a transplantable murine squa-
mous carcinoma model signiﬁcantly reduced tumor-inﬁltration
by CD11b+ myeloid cells following RT resulting in diminished
tumor growth (Ahn et al., 2010). Similarly, examination of tumor
tissue removed from head and neck cancer patients following RT
revealed marked increase in endothelial ICAM-1 expression, in
concert with increased β2 integrin-positive myeloid cell inﬁltra-
tion. The radiation-induced CXCL16 is an important mechanism
by which RT promotes CD8+ T cell inﬁltration leading to tumor
suppression. Stromal cell-derived factor-1 alpha (SDF-1α) is also
upregulated following RT in bone marrow-derived cells and cell
lines derived from brain tumors. Inhibition of the SDF-1α path-
way with a small molecule inhibitor blocking the interaction of
SDF-1α and CXCR4 prevented inﬁltration of macrophages and
signiﬁcantly delayed tumor regrowth following RT (Kozin et al.,
2010). Vaccination of prostate cancer patients with recombinant
viral-based vaccines expressing PSA, in combination with the
costimulatory molecule B7-1 and standard RT to the prostate
(70 Gy of RT in 1.8–2 Gy fractions), resulted in a threefold
increase in PSA speciﬁc T cells and evidence of generating T cells
against other prostate-speciﬁc antigens in 76% of patients (Gulley
et al., 2005).
Stereotactic body RT (SBRT)-dose radiation has been shown
to generate tumor antigen-speciﬁc T cells in mice bearing B16
tumors (Lugade et al., 2005), and comparable radiation doses are
less effective at tumor therapy when conducted in immunodeﬁ-
cientmice (Lee et al., 2009).When using aggressive, transplantable
tumor models where standard 1.8–2 Gy fractions are less effective,
and tumor-bearing survival is too short to complete an extended
fractionation schedule. A fundamental issue in stereotactic ablative
radiotherapy (SABR) is whether classical radiobiologic modeling
with the linear-quadratic (LQ) model is a valid method to assess
the biologically effective dose at the high doses typically encoun-
tered in radiosurgery. The robustness of the LQ model to predict
fractionation and dose-rate effects in experimental models in vitro
and in vivo at doses up to 10 Gy is based on the premise that cell
killing is the dominant process mediating the radio-therapeutic
response for both early and late effects including vascular effects.
However, the administration of a single high-dose of radiation
in vivo had a much greater effect than predicted by the LQ model;
they cited several examples including Leith et al. (1994) who cal-
culated that the dose to obtain a high probability of tumor control
for brain lesions would be at least 25–35 Gy using the LQ model,
whichwasmuchhigher than theobserved clinically effective radio-
surgical dose, which was in the range of 15–20 Gy. The in vitro
survival curve has goodness of ﬁt in all clinically signiﬁcant ranges
including the ablative range characteristic of SABR (Guerrero and
Li, 2004).
RADIATION THERAPY AND ACTIVATION OF
STRESS-RESPONSE PATHWAYS
Thedelivery of an ablative dose of radiation of 15–25Gywas found
to cause a signiﬁcant increase in T cell priming in draining lym-
phoid tissue, leading to reduction or eradication of the primary
tumor or distant metastasis in a CD8+ T cell-dependent fashion
in an animal model. While conventional 2 Gy doses seem inferior
at generating such responses, higher sized dose fractions may be
better than single doses (Dewan et al., 2009). Radiation cannot
only kill tumor cells releasing tumor antigens and molecules with
what are collectively called damage-associated molecular patterns
(DAMPs) that exert various immunomodulatory effects including
induction of the expression of cytokines, chemokines, and release
of inﬂammatorymediators (Figure 1; Gattinoni et al., 2005). Radi-
ation also increases the permeability of the local vasculature either
directly or through cytokine production that leads to recruit-
ment of circulating leukocytes into surrounding tissues including
APCs and effector T cells (Ganss et al., 2002). Thus, a radiation-
induced pro-inﬂammatory microenvironment within irradiated
tumors could provide DCs with maturation inducing stimuli crit-
ical for eliciting effective antigen presentation (Figure 1). The
introduction of cytokines, in particular IL-2 for cancer treatment
was a major clinical effort that had modest success. This situation
changed with the molecular cloning of human TAAs that could
be recognized by T cells, the ability to culture powerful APCs
in the form of DCs and to assess immune responses to speciﬁc
tumor epitopes using tetramer and enzyme-linked immunosor-
bent spot (ELISPOT) assays (Yee et al., 2001). The “danger”model
of immunity suggests that pathogens with associated molecular
patterns (PAMPs) and DAMPS engender an inﬂammatory milieu
that promotes the development of antigen-speciﬁc immunity
through DC maturation that allows internalization of apoptotic
and necrotic cellular debris and presentation of processed anti-
gen to T cells. Thus, administration of radiation may therefore
be considered to create an inﬂammatory setting via DC matura-
tion, induction of apoptosis, necrosis, cell surface molecules, and
secretory molecules (Figure 1). As with many other challenges,
radiation upregulates expression of immunomodulatory surface
molecules (MHC, costimulatory molecules, adhesion molecules,
death receptors, heat shock proteins) and secretory molecules
(cytokines, inﬂammatory mediators) in tumor, stromal, and vas-
cular endothelial cells. Important amongst thesemay be the upreg-
ulation of TNF family members that could promote cell killing,
not only by TNF in the microenvironment but also by radiation-
induced TNF.
Activation of Fas-mediated cell death is a mechanism by which
immune cells eliminate damaged cells, including those damaged
by RT. Thus, while whole-body radiation is “immunosuppressive”
due to triggering widespread apoptosis of immune cells via Fas,
focal radiation such as that used for treatment of many types of
solid tumors instead has limited immunosuppressive side effects,
and may actually promote changes in the local tumor microenvi-
ronment that paradoxically enhance inﬁltration and activation of
multiple immune cell types that may either foster, and/or suppress
tumor development (de Visser et al., 2006). At the most simplistic
level, a main mechanism by which ionizing radiation mediates a
biologic effect is via generation of free radicals that lead to geno-
toxic (DNA) damage, and subsequent activation of stress-response
pathways through activation of the DNA damage pathway ataxia
telangiectasia mutated (ATM). Activation of the ATM protein
pathway following RT involves activation of p53 and nuclear fac-
tor (NF)-κB transcription factors. NF-κB can also be activated
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independently of DNA damage through radiation-induced acti-
vation of TNFR-associated factors (TRAFs; Rashi-Elkeles et al.,
2006). NF-κB directly regulates expression of molecules that pro-
mote a pro-inﬂammatory immune response, including TNF-α,
IL-1 (Mori and Prager, 1996), chemokines such as CCL5 (Wick-
remasinghe et al., 2004); ICAM-1, E-selectin andVCAM-1, as well
as MHCmolecules, and expression of several anti-apoptotic genes
including Bax and Bcl-2.
ANTI-TUMOR THERAPY AND TUMOR
MICROENVIRONMENT
The tumor microenvironment contains innate immune cells [NK
cells, neutrophils, macrophages, mast cells, myeloid-derived sup-
pressor cells (MDSCs), andDC] and adaptive immune cells (T and
B lymphocytes) in addition to tumor cells and their surrounding
stroma (ﬁbroblasts, endothelial cells, pericytes, and mesenchymal
cells; de Visser et al., 2006). Myeloma cells treated with low doses
of common therapeutic agents, such as doxorubicin, melpha-
lan, and bortezomib, upregulate DNAM-1 and NKG2D ligands.
Azacytidine enhances tumor antigenicity by upregulating MHC
class I and tumor antigen expression, increasing the release of
pro-inﬂammatory cytokines and danger signals, and promoting
antigen uptake by DC and killing by NK cells. Inﬁltration of
the primary tumor by memory T cells, particularly of the Th1
and cytotoxic types, is the strongest prognostic factor in terms of
disease-free and OS at all stages of clinical disease (Pages et al.,
2010). A combined therapy of local radiation with Th1 cell could
augment the generation of tumor-speciﬁc CTL at the tumor site
and might also be effective for the treatment of distant metas-
tases. The suppressive activity of MDSCs is associated with the
intracellular metabolism of L-arginine, which serves as a substrate
for inducible nitric oxide synthase (iNOS/NOS2) that gener-
ates NO and arginase 1 (ARG 1) which converts L-arginine into
urea and L-ornithine. Tumor-derived exosome-associated Hsp72
could trigger Stat3 activation in MDSCs and determine their sup-
pressive activity in a TLR2/MyD88-dependent manner (Chalmin
et al., 2010).
INTERACTION BETWEEN TUMOR CELLS AND THE IMMUNE
SYSTEM
The tumor stroma plays an important role in the response to
high-dose per fraction radiation treatment because the vascu-
lar endothelial cell apoptosis is rapidly activated above 10 Gy
per fraction (Garcia-Barros et al., 2003), and that the ceramide
pathway orchestrated by acid sphingomyelinase (ASMase) oper-
ates as a rheostat that regulates the balance between endothelial
survival and death and thus tumor response (Truman et al., 2010).
Damage to vascular/stromal elements in tumors has also been
observed around 2 weeks after radiation exposure that was less
dependent on size of dose per fraction (Chen et al., 2009). Patho-
logical observations show profound changes in vasculature after
radiosurgery and from studies on arteriovenous malformations,
where obliteration of abnormal vasculature occurs months after
irradiation, but is rarely seen below single doses of 12 Gy climb-
ing steeply with increasing doses above this threshold (Szeifert
et al., 2007). Although lymphocyte radiosensitivity is well rec-
ognized, the effects of different doses and delivery methods
on systemic and locoregional naive, effector, or Treg or other
immunologically relevant populations is still the subject of debate.
Several authors have investigated the potential immunomodu-
latory effects of localized RT on tumors resulting in conﬂicting
reports as to whether these responses promote or interfere with
tumor reduction. This dualism is something that is to be expected
and is inherent in a system that has to promote both destruction of
pathogens and tissue healing while regulating anti-self-reactivity.
Apetoh et al. (2007) showed that radiation can trigger signals that
stimulate TLR4 on antigen-presenting DCs. Liao et al. (2009) have
shown that irradiation of DC can enhance presentation of anti-
genic peptides by the exogenous pathway and is a maturation
signal, while inhibiting internal antigen processing, and Mer-
rick et al. (2005) have shown a decrease in IL-12 production that
has a negative effect on presentation. Several reports have shown
increased expression of MHC class I and coaccessory molecules
after radiation of both tumor and host cells, while Chakraborty
et al. (2004) reported a direct effect of radiation on tumors by
modifying the phenotype of tumor cells to render themmore sus-
ceptible to vaccine-mediated T cell killing, and others have shown
that radiation-induced changes in the tumor immune microenvi-
ronment to promotes greater inﬁltration of immune effector cells
(Lugade et al., 2005).
CELL DEATH AND ANTIGEN RELEASE
Effective initiation of adaptive immune responses to cell-
associated antigen requires presentation of antigen by professional
APCs. Macrophages cross-present antigen from their environ-
ment and express an important selection of critical costimulatory
molecules; however, for effective presentation of antigens to naive
T cells in draining lymph nodes, DCs are particularly critical. For
example, apoptotic cells efﬁciently load DCs with tumor antigen,
but do not cause DC maturation (Melero et al., 2000). By con-
trast, antigen from non-apoptotic cells also loads DCs, but also
causes DCs to mature and upregulate costimulatory molecules
(Basu et al., 2000). These authors demonstrate that CD8 T cell
responses play an important role in the therapeutic outcome of
RT in animal models (Lee et al., 2009). That immune responses
may already be relevant in the success of RT suggests we have an
opportunity to increase the therapeutic margin of RT by further
enhancing the immune component.
Low-dose RT induces the apoptosis of lymphoma cells. Pri-
mary lymphoma cell culture has shown an increase in the number
of apoptotic cells after RT (Dubray et al., 1998). Another study
using ﬁne-needle cytology was coupled with in vivo imaging with
99Tc-Annexin-V scintigraphy in 11 follicular lymphoma patients,
out of which, 10 patients were concordant with cytology in both
the pre- and post-LDRT evaluation. These studies suggest that
LDRT neutralizes the anti-apoptotic properties of the characteris-
tic overexpression of Bcl-2 in follicular lymphoma cells (Langenau
et al., 2005). The overexpression of p53 induced by LDRTwas con-
ﬁrmed by p53-immunostaining with p53 expression, increasing
from 5% of lymphoma cells to >80% after LDRT. This induc-
tion of the p53 target was seen as the dominant component of
tumor cell apoptosis (Knoops and de Jong, 2008). The investiga-
tors showed that LDRT induced both intrinsic and prominently
extrinsic apoptosis pathways (Knoops et al., 2007). Therefore,
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they found an upregulation of BBC3 (Puma), BAX, PMAIP1
(Noxa), and a signiﬁcant overexpression of cleaved caspase-9
after LDRT.Death receptor genes, including TNFRSF10B (TRAIL-
R2) and FAS, were also upregulated after LDRT. Knoops et al.
(2007) also demonstrated that LDRT induced an upregulation of
macrophage activation-related genes, indicating that macrophage
activation was probably induced by signals from apoptotic cells.
No increase of CD68+ cells was observed after LDRT. These
data indicate that LDRT induces an apoptosis of follicular lym-
phoma cells that could activate innate and adaptive immunity
and contribute to the therapeutic effect observed in clinical
practice.
TLR4 expression by DCs also appears to be a prerequisite
for efﬁcient antigen presentation of tumor antigens furnished
by dying cancer cells (Apetoh et al., 2007). Th1-related genes,
including IL-18-, COP1-, and IFN-induced chemokines such as
CXCL9, CXCL10, and CXCL11, were also induced after LDRT
(Knoops et al., 2007). The response of RT outside of the radiation
ﬁeld, rarely observed in many malignancies including lymphoid
malignancies due to the abscopal effect (Robin et al., 1981). The
abscopal effect is not often observed after RT alone (Kusmart-
sev and Gabrilovich, 2002). Evidence supporting the role of RT
in promoting cross-priming and the induction of anti-tumor T
cell responses was suggested by at least one experimental model
(Chakravarty et al., 1999).When Fms-like tyrosine kinase receptor
3 ligand (Flt3-L), a growth factor that stimulates the production
of DCs were administered after the treatment of a mouse lung
carcinoma by local RT, the treated mice experienced signiﬁcant
prolonged disease-free survival. In contrast, Flt3-L alone induced
moderate delayed growth only. Mice bearing a syngeneic mam-
mary carcinoma, 67NR, in both ﬂanks were treated with Flt3-L
after local irradiation with a single dose of 2–6 Gy to only one
of the two tumors. The growth of the non-irradiated tumor was
also impaired by the combination of RT and Flt3-L; moreover,
growth of a non-irradiated A20 lymphoma in the same mice har-
boring an irradiated 67NR tumor was not affected. Demaria et al.
(2004) also showed that no such effect was observed in athymic
mice. With a murine colon adenocarcinoma model, Reits et al.
(2006) showed that radiation enhances MHC class I expression
and that anti-tumor immunotherapy with adoptive CTL cells is
active only when preceded by RT (8–10 Gy) of the primary tumor.
Similar observations were more recently described by Shiraishi
et al. (2008) with ECI301 (a chemokine secreted by various leuko-
cytes, including T lymphocytes and activated macrophages and
recruiting certain cells such as monocytes and DCs) after local
irradiation of 6 Gy. Marked inﬁltration of CD4+ and CD8+
cells was observed, not only in the irradiated site, but also at
the non-irradiated site. In a recent animal model study, Lee
et al. (2009) observed that local RT on grafted tumors gener-
ates CD8+ T cell immunity to lead to tumor reduction, reduces
local relapse, and even eradicates metastasis in some settings.
An increase of inﬁltrating T cells in the tumor microenviron-
ment and the draining lymphoid tissues was seen 1–2 weeks after
treatment with higher radiation dose (15–20 Gy in one to four
fractions).
Additional approaches to induce a CTL-mediated tumor cell
killing are basedon the in vivo activationof DCs,which should take
up tumor antigens and consecutively present tumor peptides to T
cells to achieve co-stimulation. However, macrophages recognize
and phagocytose dying tumor cells swiftly and silently and thereby
remove tumor antigens (Gaipl et al., 2007), which are recruited
by ﬁnd-me signals such as lysophosphatidylcholine (LysoPC)
secreted by RT-induced apoptotic cells. Moreover, the latter may
even cause caspase 3-dependent tumor cell repopulation by gen-
erating potent growth-stimulating signals (Huang et al., 2011). In
order to enable enhanced access of DCs to RT-induced apoptotic
and necrotic tumor cells is to block their clearance bymacrophages
with the PS-binding protein Annexin A5 (AnxA5; Bondanza et al.,
2004; Frey et al., 2009). The growth of syngeneic tumors is signif-
icantly retarded by a single injection of AnxA5 around the tumor.
The combination of RT with AnxA5 resulted in the most effective
inhibition of tumor growth (Frey et al., 2009). In vivo experiments
with immune-competent mice bearing syngeneic tumors have
proven that AnxA5 increases the immunogenicity of tumor cells.
The injection of irradiated tumor cells pre-incubated with AnxA5
cured established tumors in about 50% of the animals, while the
injection of irradiated tumor cells only resulted in<10% of tumor
free mice (Bondanza et al., 2004). Targeting of PS on therapy-
induced dying and on viable metastatic cells could therefore both
lead to efﬁcient anti-tumor immune responses by promoting
uptake of the tumor cells by DCs, to mention here one of mul-
tiple possible modes of action resulting from the shielding of PS
(Frey et al., 2012).
RADIATION THERAPY-INDUCED IMMUNOGENIC
CELL DEATH
Radiation of tumor cells generally produces two responses: pro-
liferative arrest (which in the case of senescence is indeﬁnite) or
cell death, which occurs by several mechanisms including apop-
tosis, necrosis, autophagy, or mitotic catastrophe (Galluzzi et al.,
2007). Autophagy is marked by sequestration of large parts of the
cytoplasm in autophagic vacuoles typically before cells undergo
apoptosis. Finally, mitotic catastrophe is described by prolonged
mitotic arrest with associatedmicro- and/ormultinucleation prior
to undergoing death. Radiation-mediated cell death is generally
thought to occur primarily through either apoptosis or mitotic
catastrophe. Immunization with tumor cells treated with either
chemotherapy or RT prevented regrowth of tumors in ∼30%
of mice as compared to mice immunized with untreated tumor
cells. When cells were harvested from draining lymph nodes in
immunized mice, and re-challenged ex vivo, only lymph node
cells from mice immunized with tumor cells treated with RT
produced IFN-γ in response to re-challenge. Protective immu-
nization in this scenario was dependent on the presence of TLR4
on DCs and its ligand HMGB1, both released by tumor cells
following RT (Apetoh et al., 2007). Two other factors, calretic-
ulin and ATP, also signiﬁcantly contribute to immunogenic cell
death, in a manner similar to HMGB1, where cell death trig-
gers rapid translocation of calreticulin to the surface of cells
thereby promoting antigen presentation by dying cells and DCs
(Perez et al., 2009). Cytotoxic therapies (chemotherapy and RT)
induce rapid release of ATP from cells. ATP acts on the P2X(7)
purinergic receptor expressed by DCs, leading to activation of
the NOD-like receptor family, pyrin domain containing-3 protein
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(NLRP3)-dependent caspase-1 activation complex also known as
the inﬂammasome. Inﬂammasome activation leads to release of
pro-inﬂammatory cytokines such as IL-1β, which are important
for priming T cells. When components of this pathway (NLRP3,
caspase-1 or IL-1R) are absent, reduced T cell responses toward
cells killed by chemotherapyorRTare observed (Ghiringhelli et al.,
2009), thus indicating that release of ATP from dying cells is a
critical aspect of immunogenic cell death and anti-tumor immu-
nity. Innate leukocytes, including DCs, macrophages, NK cells,
and mast cells, are referred to as “ﬁrst responders” to inﬂam-
matory mediators, largely based on the fact that they are often
pre-stationed in tissues. RT induces opposing responses in tumors
with regards toDCs: directly irradiatedDCs are less effectiveAPCs,
however, the tumor microenvironment generated by RT enhances
APC capabilities of DCs. Tumor-inﬁltratingmacrophages, derived
from circulating monocytes, make up a substantial component
of the leukocyte inﬁltrate in solid tumors (Mantovani and Sica,
2010). Using human macrophage-derived cell lines, Lambert and
Paulnock (1987) observed that RT enhancedmacrophage cytolytic
activity. Other groups have reported that low-dose whole-body
RT increased expression of TLR4/MD2 and CD14 expression on
murine peritoneal macrophages, leading to increased secretion
of anti-tumor cytokines including IL-12 and IL-18, thus indi-
cating that RT increases anti-tumor potential of macrophages
(Shan et al., 2007).
Mast cells are pre-stationed in many tissues where they act
as important sentinel cells capable of mounting rapid responses
to tissue damage. Heissig et al. (2005) reported that LDRT fos-
teredmast cell-dependent vascular regeneration in a limb ischemia
model where RT promoted vascular endothelial growth factor
(VEGF) production by mast cells in a matrix metalloproteinase-9
(MMP-9)-dependent manner. RT, through MMP-9 upregulated
by VEGF in stromal and endothelial cells, induced release of Kit-
ligand (KitL) and promoted migration of mast cells from bone
marrow to the ischemic site similar to RT effects in the tho-
racic cavity where mast cell density increased in bronchoalveolar
lavage ﬂuid (Heissig et al., 2005). RT and adaptive immunity in
experimental rodent models of cancer development, e.g., brain,
sarcoma, lung, and breast, RT alone or in combination with DC
or immunostimulatory therapies enhanced generation of anti-
tumor responses mediated by CTL cells (Matsumura et al., 2008).
RT alone can also stimulate anti-tumor T cell-based immunity
when given at high doses by increasing the number of acti-
vated CD8+ T cells. In 4T1 mammary tumors, recruitment
of CTL cells is dependent on CXCR6, a receptor for CXCL16.
RT in combination with anti-CTLA-4 mAB increases recruit-
ment of CXCR6+ CD8+ T cells (Matsumura et al., 2008). In
orthotopically transplanted sarcoma and carcinomas, presence
of macrophages was inversely correlated with tumor regres-
sion following RT (Milas et al., 1987). In melanoma, local RT
of implanted tumors increased the number of APCs in drain-
ing lymph nodes and increased the number of CD11b+ cells
in tumors (Lugade et al., 2005). CD11b+ myeloid cells (a por-
tion of which are macrophages) contribute growth factors such
as VEGF and MMP-9 that supports angiogenic programs in
growing tumors. Preventing inﬂux of CD11b+ myeloid cells fol-
lowing RT results in enhanced RT effects likely due to their
increased expression of T cell suppressive molecules iNOS and
ARG 1 (Meng et al., 2010). Examination of tumor cells exposed
to ionizing radiation in vitro indicates that RT induces expres-
sion of NKG2D ligands, an activating receptor for NK cells
(Kim et al., 2006).
Robust acute inﬂammation could be triggered by sterile cell
death which induces DAMP exposed on the plasma membrane
or secreted extracellularly. These cell-derived DAMP, such as
uric acid, DNA (speciﬁcally unmethylated CpG-rich regions),
HMGB1, SAP130, S100 proteins, and Hsp could stimulate an
IL-1- and inﬂammasome-dependent response (Osterloh et al.,
2008). Other pro-inﬂammatory stress molecules released by dying
cells include Hsp70, a stress-response protein with a role in
binding defective proteins and presenting them on the surface
of cells. When exposed to RT, pancreatic and colon carcinoma
cell release Hsp70, thereby targeting them for lysis by NK cells
(Gehrmann et al., 2005). That NKG2D ligands and Hsp 70 ren-
der cells more susceptible to NK cell-mediated cytolysis indicates
that RT-stimulated NK activity may be an important component
of RT-induced immune responsiveness. Apoptotic microparticles
could transfer chemokine receptors and arachidonic acid between
cells, activates complement, promote leukocyte rolling, and stim-
ulate the release of pro-inﬂammatory mediators. LysoPC, but
none of the LysoPC metabolites or other lysophospholipids, rep-
resents the essential apoptotic attraction signal able to trigger
a chemotactic response through phagocyte receptor G2A (Peter
et al., 2008). The prototypical DAMP-HMGB1 is released with
sustained autophagy, late apoptosis, and necrosis. HMGB1 could
act as chemotactic and/or activating factors formacrophages, neu-
trophils, and DC (Apetoh et al., 2007). Forced expression of CD39
(NTPDase-1, an ecto-apyrase responsible for the degradation of
NTP) could abrogate the chemoattractant activity of apoptotic
cells (Elliott et al., 2009). Myeloid leukemia,migrating hematopoi-
etic progenitors, and also solid tumors were found to overex-
press CD47, resulting in a reduced uptake by SIRPα-expressing
macrophages.
CONCLUSION
To design effective therapies for the future, it remains to be deter-
mined to what degree this endogenous response can be relied
upon to clear tumors once they have successfully emerged from
immune control. The radiation is cytotoxic to lymphocytes, and
it is possible that prolonged fractionation limits the capacity of
adaptive immunity to inﬂuence the outcome of RT. On the other
end of the radiation dose scale, the advents of hypofractionated
RT may permit more direct translation of the lessons learnt in
animal models into clinical research and minimize the negative
effects of fractionated radiation on tumor-site immune responses.
With the continuing evolution of technology in RT it may become
more feasible to optimize the cytotoxic component of radiation
while simultaneously taking into account optimal immune activa-
tion. LDRT is now widely acknowledged to be very active against
indolent lymphomas and is a useful tool in the management of
this disease with virtually no toxicity. In clinical practice, the
best methods to develop active combinations with RT and current
treatments such as rituximab, immunotherapy, and chemotherapy
remain to be studied. Combination immunotherapy and radiation
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approaches are being translated into the clinic where intratu-
moral DCs injection with coordinated irradiation and intro-
duction of autologous, unmanipulated DCs have been the
subject of anti-tumor therapy. At present, SABR represents
an exciting, effective, yet empirically designed RT. In addi-
tion, SABR could be optimized for use with immunotherapeutic
approaches so as to better generate tumor antigen-speciﬁc cellular
immunity.
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